• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Vowst as a Potential Option for Patients With Recurrent C Difficile Infections

Opinion
Video

The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut bacteria to restore microbiome diversity, distinguishing itself from traditional antibiotics in preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment.

Related Videos
1 expert is featured in this series.
5 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.